(SLDB) – Management Comments
-
Solid Biosciences (SLDB) Reports Q4; Announces 2-Year Efficacy and Safety Data from the Ongoing Phase I/II IGNITE DMD Clinical Trial of SGT-001
-
Solid Biosciences (SLDB) and Forge Biologics Announce Viral Vector Contract Development and cGMP Manufacturing Partnership
-
-
-
-
-
-
-
-
-
-
-
-
Back to SLDB Stock Lookup